Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 ...

Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product ...

It's an important meeting. What's the plan for flu vaccines this year," Dr. Paul Offit, a member of the FDA advisory committee and director of the Vaccine Education Center at Children's Hospital ...

DURHAM, N.C. - Biotechnology company Humacyte, Inc. (NASDAQ:HUMA), currently trading at $3.04 and down over 21% in the past week, has announced the commercial launch of its bioengineered human tissue ...

Allow the Sale, Sharing or use of My Personal information for Targeted Advertising If you switch this toggle to “no,” we will not sell or share your personal information with third parties for ...

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their ...

The company is also making good progress with its second FDA-approved product, Rezlidhia (olutasidenib). The drug is indicated for the treatment of adult patients with relapsed or refractory (R/R ...

In December, the FDA finalized a rule that updates the nutritional requirements a human food item must meet to claim on its packaging that it is “healthy.” That rule was published with an ...

Beginning Friday night, FDA employees overseeing medical devices, food ingredients and other key areas received calls and emails notifying them that their recent terminations had been “rescinded ...

Recent mass layoffs at the US Food and Drug Administration (FDA) under the Trump Administration are expected to affect several industries, including AI, healthcare, and food. It will slow down medical ...

Staff units evaluating high-tech surgical robots and insulin-delivery systems were gutted by Trump layoffs even though industry fees, not taxpayers, financed the employee salaries. By Christina ...